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Essentials
• Variants at ABO, von Willebrand Factor (VWF) and 2q12 contribute to the variation in plasma in VWF.
• We performed a genome-wide association study of plasma VWF propeptide in 3,238 individuals.
• ABO, VWF and 2q12 loci had weak or no association or linkage with plasma VWFpp levels.
• VWF associated variants at ABO, VWF and 2q12 loci primarily affect VWF clearance rates.
Summary.
Background: Previous studies identified common variants at the ABO and VWF loci and unknown variants in a chromosome 2q12 linkage interval that contributed to the variation in plasma von Willebrand factor (VWF) levels. Whereas the association with ABO haplotypes can be explained by differential VWF clearance, little is known about the mechanisms underlying the association with VWF single-nucleotide polymorphisms (SNPs) or with variants in the chromosome 2 linkage interval. VWF propeptide (VWFpp) and mature VWF are encoded by the VWF gene and secreted at the same rate, but have different plasma half-lives. Therefore, comparison of VWFpp and VWF association signals can be used to assess whether the variants are primarily affecting synthesis/secretion or clearance. Methods: We measured plasma VWFpp levels and performed genome-wide linkage and association studies in 3238 young and healthy individuals for whom VWF levels had been analyzed previously. Results and conclusions: Common variants in an intergenic region on chromosome 7q11 were associated with VWFpp levels. We found that ABO serotype-specific SNPs were associated with VWFpp levels in the same direction as for VWF, but with a much lower effect size.
Neither the association at VWF nor the linkage on chromosome 2 previously reported for VWF was observed for VWFpp. Taken together, these results suggest that
Introduction
Plasma von Willebrand factor (VWF) levels vary approximately five-fold among healthy individuals, and are highly heritable [1] [2] [3] [4] [5] . Individuals with VWF levels at the extremes of the normal distribution are at risk for common disorders of hemostasis: low levels cause the common bleeding disorder type I von Willebrand disease (VWD); and high levels are associated with increased risks for both venous and arterial thrombosis [6, 7] . Therefore, identification of the genetic factors affecting VWF levels may lead to improved, personalized care for patients with VWD, arterial thrombosis, and venous thromboembolic disease [8] . Previous genome-wide association studies (GWASs) demonstrated that common variants at ABO, VWF and other loci explained~12% of the variation in plasma VWF levels [9] . More recently, we reported genome-wide linkage and association analyses of plasma VWF levels in a cohort of young healthy individuals [3] , and confirmed the association between ABO A1 and B alleles with elevated VWF levels relative to the O and A2 alleles. At VWF, haplotypes containing common variants near the factor VIIIbinding (D 0 domain) and propeptide-coding (D1 and D2 domains) regions were also significantly associated with VWF levels [3, 10] . Using the sibling structure in our cohorts, we performed linkage analysis, and identified an interval on chromosome (Chr) 2q12 explaining~19% of the variation in VWF levels [3] . Although the effect may not be direct [11] , the major allelic variants at ABO influence VWF levels through altered VWF clearance [12] [13] [14] , whereas the basic mechanisms underlying the effect of the variants in VWF and in Chr 2q12 remain unknown.
A specialized post-translational modification system facilitates the storage and secretion of VWF multimers [15] . The VWF propeptide (VWFpp) is cleaved from pro-VWF dimers, but remains non-covalently bound to the developing VWF multimers until both are secreted into flowing blood. VWFpp is rapidly cleared from the circulation, with a half-life of 2-3 h, whereas multimeric VWF has a longer half-life of 8-12 h [16] . As alterations in VWF synthesis or secretion would be expected to affect VWF and VWFpp levels similarly, relative differences in the steady-state levels of these two proteins in plasma should reflect differences in their clearance rates. For this reason, elevation in the VWFpp/VWF ratio has been used to differentiate the subset of individuals with VWD resulting from rapid clearance of VWF from those with reduced synthesis or secretion [17, 18] .
To identify genetic variants affecting plasma VWFpp levels and to determine whether single-nucleotide polymorphisms (SNPs) previously associated with VWF variation operate primarily through altered synthesis/secretion or clearance mechanisms, we measured VWFpp levels in plasma samples from the Genes and Blood Clotting Study (GABC) and the Trinity Student Study (TSS), in which VWF levels had already been measured and their association results reported [3] . Using an initial measure of VWFpp in the GABC cohort, we identified a strong association with a non-synonymous SNP in the VWFpp-coding portion of VWF. However, this association was not present when a different set of mAbs were used to determine VWFpp levels, suggesting that an altered epitope resulting from this SNP had generated the apparent association. We therefore used only VWFpp assay results without interference from this altered epitope in association and linkage studies, and identified significant associations between VWFpp and variants at ABO and a new locus on Chr 7. Comparison of these results with those of our previously reported VWF studies [3] suggest that variants at VWF and the Chr 2 linkage interval modify VWF levels mainly through clearance mechanisms.
Materials and methods

GABC
One thousand one hundred and eighty-nine healthy siblings between the ages of 14 years and 35 years were recruited from the students and staff at the University of Michigan, Ann Arbor between June 2006 and January 2009 [3, 19] . Subjects who reported that they were pregnant or had a known bleeding disorder or chronic illness requiring regular medical care were excluded. All subjects gave informed consent prior to their participation [20] . 
Plasma VWFpp levels
VWFpp levels were measured in the GABC and TSS cohorts with AlphaLISA (Perkin-Elmer, Waltham, MA, USA) [3] . To create VWFpp-specific AlphaLISA assays, mAbs were produced in the Blood Center of Wisconsin Hybridoma Core Laboratory (Milwaukee, WI, USA) by immunizing mice with purified recombinant human VWFpp. mAbs were purified from ascites, and epitope mapping was performed by the use of standard ELISAs, with truncated fragments of recombinant VWFpp as targets (Fig. S1 ). For TSS plasma samples, which were collected with EDTA as an anticoagulant, 0.8 mM CaCl 2 was added to the assay buffer to correct for signal loss associated with the presence of EDTA (Fig. S2) .
VWFpp levels were calculated on the assumption of a 1 : 1 ratio of VWF to VWFpp in laboratory control plasma from pooled donors (FACT; George King Biomedical, Overland Park, KS, USA). Each sample was independently assayed at least four times. The mean sample coefficients of variation were 1.0% (GABC, anti-D2), 1.1% (GABC, anti-D1), and 2.8% (TSS, anti-D1). After quality control, 3381 subjects (1110 GABC; 2271 TSS) had VWFpp levels available for heritability analysis, and 3238 had them available for association and linkage testing.
Phenotype data processing
The raw VWFpp distribution was normalized by log transformation, and adjusted for the effects of age, gender, and population genetic structure. We evaluated the correlation between each of the first 10 principal component (PC) scores and the age-corrected and gender-corrected VWFpp levels for GABC and TSS separately, and used Pearson's correlation coefficients and P-values to determine which PCs have a significant impact (P < 0.05) on the phenotype. After analyzing Pearson's correlation coefficients, P-values and genomic control (GC) factors, we selected the PC(s) that were highly correlated with the two traits and resulted in the lowest GC factors. For use in GWAS and linkage studies, log-transformed VWFpp levels were adjusted for age, gender, and the selected PC (s): PC2 and PC7 for GABC, and PC4 for TSS.
Genotyping, imputation, and quality control GABC: Details of the genotyping and data-cleaning process have been previously published [3, 20, 21] . The final cleaned dataset contained 763 195 SNPs and 1152 subjects representing 489 sibships. Imputation was carried out by the GENEVA Consortium Data Coordinating Center, using BEAGLE v3.3.1 [22] on a set of 767 243 genotyped SNPs. The final dataset included~7.50 million SNPs. We then removed SNPs with low imputation quality (R 2 < 0.3) and low allele frequency (minor allele frequency [MAF] of < 2%), resulting in~5.95 million SNPs.
TSS: After extensive cleaning, the final dataset contained 757 577 SNPs.
For imputation, we first pre-phased the cleaned dataset by using SHAPEIT2 v2.r778 [23] , and then used IM-PUTE2 v2.3.0 [24] and the 1000 Genomes Phase I release v3 integrated haplotypes (produced by the use of SHAPEIT2 in December 2013) for imputation. This generated 10 520 121 imputed SNPs. After removal of the SNPs with low imputation quality (R 2 < 0.3), low allele frequency (MAF of < 2%), and low call rate (< 95%), and that failed the test of Hardy-Weinberg equilibrium (P < 1.0 9 10 À6 ), the final dataset contained~7.37 million SNPs in 2304 individuals. The TSS and GABC imputed datasets had~4.51 million SNPs in common; this set was used for the meta-analyses. The genome-wide significance level was set at P = 5.0 9 10
À8
, based on a conservative Bonferroni correction for~1 million independent tests.
Genetic analyses
Population substructure Owing to the presence of sibships of different sizes, GABC samples were analyzed with a two-step approach [25] , as detailed previously [3, 19] .
Association analyses For the GABC cohort, we performed single-SNP association analysis of the transformed and adjusted VWFpp antigen levels by using the imputed set of~5.95 million SNPs. To account for the inferred relatedness and subtle population stratification, we applied a mixed linear model implemented in EMMAX [26] . For the TSS cohort, we performed single-SNP association tests on the set of~7.37 million imputed SNPs by using PLINK (v1.07) [27] , assuming an additive mode of allelic effect. For both cohorts, we calculated the GC factor [28] to assess the degree of residual stratification.
Meta-analysis
We performed a meta-analysis of GABC and TSS association results with a sample size-weighted approach on the common set of~4.51 million imputed SNPs by using METAL [29] . The GC factor was near 1 for both analyses, i.e. 0.972 and 1.013 for GABC (EMMAX) and TSS (PLINK), respectively, and the association statistics were corrected to reach a GC factor of 1.000 by the use of METAL before being used in the meta-analysis. Regional plots of the significant findings were produced with LOCUSZOOM [30] .
Detection of an antibody-specific SNP association with VWFpp VWFpp levels were initially determined by using a pair of monoclonal anti-VWFpp D2 domain antibodies (Fig. S1 ). In the European subset (n = 934) of GABC, a single SNP, rs1800378(T), with a MAF of 33% in our cohort, was associated with VWFpp (P = 1.15 9 10
À12
, b = 0.051 IU dL À1 per allele in an additive model) ( Fig. S3A-C ). This SNP encodes a histidine to arginine substitution at position 484 in the D2 domain of VWFpp, and is predicted by POLYPHEN-2 [31] to be a benign variant. It was not significantly associated with plasma VWF levels (P = 0.52). We repeated the VWFpp measurement with a second pair of anti-VWFpp D1 domain antibodies (Fig. S1 ). Although the log-transformed VWFpp levels measured with the anti-D2 domain antibodies were highly correlated with those measured with the anti-D1 domain antibodies (Spearman's q = 0.97, P < 0.0001), VWFpp levels measured with the anti-D1 domain antibodies did not produce a significant signal at rs1800378 (P = 0.061; Fig. S3D ,E), suggesting that VWFpp bearing this coding change has altered affinity for the anti-D2 domain antibody pair. We used VWFpp levels measured with the anti-D1 domain antibodies in subsequent association and linkage analyses.
Linkage analysis Linkage analysis was carried out with MERLIN-REGRESS [32] on the European sibling subset of GABC and the sibling subset of TSS (n = 138). We employed a clustering algorithm and a permutation-based locus-counting approach to calculate empirical P-values for the top linkage signals, as previously described [3] .
Starting with the MERLIN-REGRESS output, the subsequent analysis was carried out with custom scripts in R [33] .
Heritability analysis For the combined sibling subset of TSS and 1139 GABC individuals (557 sibships), we used two pedigree-based methods for estimating heritability, i.e. intraclass correlation and MERLIN-REGRESS (v1.1.2), as previously described [3, 19, 32] .
Variance explained by association and linkage regions The Genome-wide Complex Trait Analysis (GCTA) package [34] was used to estimate the proportion of variation in VWFpp levels explained by the entire genome, the top associated SNPs, or intervals representing individual genes or loci, as previously described [3, 19] .
Haplotype-based association analysis PLINK [27] was used to carry out haplotype association with the one-degree-offreedom haplotype-specific test. ABO serotypes (A1, A2, O, and B) were tagged by the three SNPs rs687289, rs8176704, and rs8176749, as reported by Barbalic et al. [35] .
Results
VWFpp levels are highly heritable
Details of the demographic characteristics of the TSS and GABC cohorts are shown in Table 1 . There were differences in the distribution of unadjusted VWFpp levels (Fig. S4A) between the GABC and TSS cohorts (Kolmogorov-Smirnov test, P = 0.0001), with median VWFpp levels of 100.0 IU dL À1 in GABC and 86.1 IU dL À1 in TSS (Table 1 ). These differences may have resulted from sample collection in acid citrate dextrose for GABC versus in EDTA for TSS that was not adequately corrected for by additions of CaCl 2 to the assay buffer (see Materials and methods). However, when the VWFpp values were logtransformed, mean-centered within each cohort, and adjusted for age, sex, and the population structure, the distribution differences between GABC and TSS disappeared (Fig. S4B) . On the basis of on interclass correlation among the siblings in the GABC and TSS cohorts, the narrowsense heritability of VWFpp was 77.6%, consistent with the value of 80.4% obtained with MERLIN-REGRESS. These heritability estimates are similar to those we reported for VWF, i.e. 64.5% and 66.3%, using interclass correlation and MERLIN-REGRESS, respectively [3] . There was a significant positive correlation between the adjusted VWFpp and VWF levels, with Spearman's rank correlations (q) of 0.52 for the GABC cohort (P < 0.0001) and 0.53 (P < 0.0001) for the TSS cohort, respectively (Fig. S5AB) .
Common variants at ABO and Chr 7q11 are associated with VWFpp levels
VWFpp association results for the GABC and TSS cohorts ( Fig. S3D and Fig. S6A , respectively) were combined in a meta-analysis using a common set of~4.51 million genotyped and imputed SNPs. Two regions with significant associations were identified (Table 2) . First, eight SNPs on Chr 9q34 at the ABO locus showed significant associations (Fig. 1A,B,D) , with the top SNP, rs8176746 (P = 1.1 9 10 À13 ), encoding an L266M substitution in ABO and tagging the common ABO B allele. All SNPs at the ABO locus (N = 28) explained 7.40% of the variation in the adjusted VWFpp levels as compared with 19.6% of the variation in the adjusted VWF levels (Table 3) . Second, seven associated SNPs were identified on Chr 7q11.22 in an intergenic region, with the top SNP being rs56835261 (P = 1.6 9 10 À8 ) (Fig. 1C) . Taken together, the 15 significant SNPs at these two loci explained 3.50% of the variation in the adjusted VWFpp levels (Table 3) . A heterogeneity analysis of these top SNPs showed no significant difference across the two cohorts (all with I 2 = 0% and P > 0.05). When a conditional analysis using the top meta-analysis SNP, i.e. rs8176746, was performed, no new signal arose at the ABO locus or elsewhere, and the signal at Chr 7q11, i.e. rs56835261, was reduced to just below the threshold for significance (P = 5.5 9 10 À8 ).
ABO haplotypes are associated with VWFpp levels, but less strongly than with VWF levels Twenty-eight SNPs at the ABO locus explained 7.40% of the variation in VWFpp levels as compared with 19.6% of the variation in VWF levels (Table 3 ) [3] . A1, B, O and A2 tagging haplotypes had the same direction of effect in both VWFpp and VWF associations, but the effect sizes were weaker for VWFpp than for VWF ( Table 4) . The difference between the sizes of effects of the ABO haplotype on VWF levels and VWFpp levels is evident when the adjusted VWF and VWFpp levels are plotted according to ABO haplotypes predicted by three ABO SNPs [35] (Fig. 2 ). There were significant differences in VWF levels between the homozygous low group (A2/ O, O/O, and A2/A2) and the homozygous high group (B/B, A1/A1, and B/A1) (t-test, P = 4.4 9 10 À55 ), and the homozygous high group and the heterozygous high/ low group (A2/B, B/O, A1/O, and A1/A2) (t-test, P = 2.8 9 10 À10 ) ( Fig. 2A) . For VWFpp levels, significant differences existed between the homozygous low group and the homozygous high group (t-test, P = 5.0 9 10 À6 ), and the heterozygous high/low group and the homozygous low group (t-test, P = 5.6 9 10
À9
), but not between the homozygous high group and the heterozygous high/low group (t-test, P = 0.14) (Fig. 2B) .
No significant linkage signal at Chr 2q12 for VWFpp
Using the sibling subset of GABC and linkage disequilibrium-based 36 658 SNP clusters, we performed linkage studies to identify additional genetic factors affecting VWFpp levels. Unlike VWF, which had a significant linkage signal at Chr 2q12 and Chr 9q34 (containing ABO) [3] (Fig. 3A) , VWFpp had no significant signal in the Chr 2q12 VWF linkage interval, or at any loci elsewhere (Fig. 3B) .
Comparisons of association results of VWF and VWFpp suggest differential clearance mechanisms for the ABO, VWF and Chr 7 regions
If a DNA variant affected the clearance process for either VWF or VWFpp, we would expect it to show different association signals for VWF and VWFpp. Conversely, if a variant affected the shared synthesis or secretion processes for VWF and VWFpp, it would be expected to generate similar association effect sizes and directions for both VWF and VWFpp. Consistent with this expectation, rs687289 and rs8176746, tagging the O and B alleles of ABO, respectively, had a strong association with VWF and a much weaker association with VWFpp, suggesting that, although these ABO SNPs were associated with both VWF traits, the difference in the magnitude of their effects is best explained by unequal SNP effects on the rates of clearance from the circulation. This result agrees with the well-described ABO blood group association with VWF clearance, but is a new finding for VWFpp (Table 5 ; Fig. S7A,B) .
The top SNP at the VWF locus was rs1063856, which encodes a non-synonymous variant (T789P) in the D 0 domain of VWF. However, in the VWFpp analysis, no VWF SNPs reached genome-wide significance. rs1063856 had the same effect directions for both VWF and VWFpp, but the effect size was greater for VWF (Table 5 ; Fig. S7C ), again consistent with a variant primarily affecting a VWF clearance mechanism. In the meta-analysis, seven SNPs in the intergenic regions of Chr 7 were associated with VWFpp. These SNPs were not significant in previous VWF GWASs [3, 9] , and had a lower effect size for VWF, suggesting the presence of a variant affecting the clearance of VWFpp but not that of VWF (Fig. S7D) .
Discussion
This study reports the first heritability, linkage and genome-wide association analyses of VWFpp levels, with comparisons with previously published linkage and association studies of plasma VWF measured in the same cohorts. We found that both plasma VWF and VWFpp levels are highly heritable quantitative traits.
In our initial analysis of the VWFpp levels measured with a pair of anti-D2 domain antibodies, we detected a significant association for a non-synonymous SNP in the D2 domain of VWF. However, we determined that this result was probably an artefact resulting from an amino acid substitution affecting antibody binding, and not a genuine association with VWFpp levels. Similar apparent associations with non-synonymous SNPs in cis have been identified for several plasma proteins in the hemostatic system [3, [36] [37] [38] . In addition, according to the NHGRI GWAS catalog [39] (accessed on 16 December 2015), of the 150 reported GWASs of quantitative protein traits relying on antibody-based assays, 62 (40%) yielded significant associations with SNPs residing at the locus encoding the protein under investigation. Although these SNPs may tag variants altering the level of the corresponding proteins, our findings with rs1800378 and VWFpp suggest that a subset of these signals may be false positives generated by altered antibody binding affinities for the variant protein. This finding is similar to a report of a common VWF SNP causing altered VWF:ristocetin cofactor activity levels, but not changing VWF levels [40] . These observations also resemble the caveats reported for gene expression quantitative trait locus (QTL) analysis, where some cis-expression QTLs (eQTLs) may be attributable to variants in cDNA directly affecting hybridization to microarray probes [41, 42] . The implication for the genomics community is that extra caution is warranted in the interpretation of cis-QTLs for antibody-based protein traits. We suggest that non-synonymous SNP associations should be replicated with alternative antibody reagents.
Many GWASs have found significant associations with variants in intergenic regions that presumably regulate gene expression. This study identified an association between VWFpp and 14 SNPs in an intergenic region on Chr 7 that were~725 kb upstream from the nearest coding sequence of AUTS2. None of these SNPs affect gene expression, according to an eQTL database [43] (accessed show the comparisons between the homozygous high (BB, A1A1, and BA1), heterozygous high/low (A2B, BO, A1O, and A1A2) and homozygous low (A2O, OO, and A2A2) groups (with 'high' and 'low' defined by their adjusted VWF levels). on 7 January 2016). For nine of these SNPs, 'minimal binding evidence' was found by RegulomeDB [44] , based on DNase-seq and transcription factor binding motif hits (accessed on 25 January 2016); and 12 of these SNPs had an effect on at least one regulatory motif according to HaploReg [45] (version 4.1, accessed on 25 January 2016). There was no significant association of these SNPs with VWF levels, which suggests that they may regulate the expression of a factor that affects the clearance of VWFpp from the circulation independently of VWF. As these SNPs were detected in the meta-analysis alone, further replication in an independent cohort is necessary for confirmation.
ABO blood group is an established modifier of plasma VWF levels. As other groups have reported [46, 47] , we found a significant difference in VWF levels between high group homozygotes and high/low group heterozygotes, suggesting an ABO allelic dose effect altering steady-state levels of plasma VWF, as opposed to a clean dominant affect of A1-type and B-type antigens, where we would expect to find no differences between homozygous high group and high/low group heterozygotes. Previous studies have failed to detect an association between ABO blood groups and VWFpp levels [12, [48] [49] [50] . Given the sample size of 3238 individuals, our finding of a significant association was probably attributable to increased power as compared with earlier studies, which had smaller sample sizes, ranging from 47 to 948 individuals. There are four potential N-linked glycosylation sites on VWFpp, but no occupancy of ABO blood group antigens on these sites has been reported [49] . However, Groeneveld et al. [11] . recently reported a study of VWF clearance suggesting that the genotype of the individual is the primary determinant of ABO-associated VWF clearance, and not the ABO glycosylation pattern on VWF itself. If this finding applied to VWFpp as well, then the glycosylation pattern on VWFpp would be irrelevant. Nevertheless, the effect of the major ABO haplotypes on VWF and VWFpp was in the same direction, suggesting a shared mechanism of action, but functional studies will be required to clarify how ABO antigens alter VWFpp clearance. For the VWF SNPs, the difference in effect size between VWF and VWFpp and the absence of significant associations with VWFpp levels suggest that the VWF variants operate through an altered clearance pathway(s). Investigators have cloned and functionally characterized many VWF mutations causing VWD [51] , but common VWF variants causing variations in VWF levels in healthy individuals have not yet been identified or well characterized. Previous studies by our group and others have documented an association of VWF levels with common variants at the VWF locus [3, 9, 10] . The top VWF SNP in our meta-analysis, i.e. rs1063856(C), encodes a missense variant in the D 0 domain of VWF, and could be a functional variant driving the association. Our study suggests that the VWF haplotype tagged by this SNP encodes a form of VWF with a prolonged plasma half-life as compared with the VWF encoded by the reference allele, and that the effect of this haplotype on VWFpp clearance is much weaker. The precise mechanism for the altered clearance of this VWF variant remains unknown.
Linkage analysis of VWFpp did not detect a QTL at Chr 2q12, which was previously identified as a QTL for VWF levels. The linkage interval contains many potential candidate genes, and our results suggest that genes potentially affecting protein clearance, such as those encoding sialotransferases (ST3GAL5) or lectin receptors (LMAN2L), are more attractive candidates than genes likely to affect synthesis or secretion pathways, such as those encoding SNARE complex (VAMP5 and VAMP8) or Golgi-associated (TGOLN2) proteins.
Our study used the comparative analysis of VWF and VWFpp to distinguish genetic variants affecting VWF or VWFpp clearance from those affecting synthesis and secretion. However, as a novel strategy to interpret differential associations of two related proteins, our analyses had several limitations. First, by necessity, the measurement of VWFpp was performed with a different pair of antibodies from those employed in the VWF assay. This allows for differences in assay performance that may have led to false-negative associations of VWFpp, suggesting differential clearance mechanisms. However, this scenario is not very likely, as the heritability of VWFpp levels was very similar to that of VWF levels, and both traits were measured in the same cohorts. Second, variants that were associated with both clearance and synthesis/secretion rates of VWFpp may have been undetectable in our analysis, e.g. a variant associated with both decreased secretion rates and decreased clearance rates. Although our results strongly suggest a clearance mechanism for the major common modifiers of VWF, functional studies will be required for confirmation.
Taken together, the results of our VWFpp analyses provide new insights into the mechanism of action for common variants (at ABO and VWF) and potentially rare variants (in the Chr 2 lineage region) altering plasma VWF levels, and demonstrate a newly discovered association signal for VWFpp at Chr 7. This study is expected to facilitate the identification of functional variants controlling VWF variation, and improve our understanding of the molecular mechanisms in individuals with bleeding disorders resulting from low VWF levels, or in individuals at risk for venous thromboembolic disease resulting from elevated VWF levels [52] . 
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